OMER — Price & Forward EBITDA

Forward EBITDA (M)

Float Short %

25.39

Margin Of Safety %

Put/Call OI Ratio

0.37

EPS Next Q Diff

-3.53

EPS Last/This Y

-1.49

EPS This/Next Y

2.85

Price

10.98

Target Price

43.67

Analyst Recom

1.8

Performance Q

-28.7

Upside

-259.4%

Beta

2.59

Ticker: OMER

16 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-03-09	OMER	11.28	0.42	0.32	44780
2026-03-10	OMER	11.72	0.42	0.06	44732
2026-03-11	OMER	11.94	0.42	0.02	45058
2026-03-12	OMER	11.43	0.42	0.09	45207
2026-03-13	OMER	11.42	0.42	0.12	45207
2026-03-17	OMER	11.27	0.41	0.00	46323
2026-03-18	OMER	10.95	0.39	0.19	47609
2026-03-20	OMER	11.02	0.39	3.17	48225
2026-03-25	OMER	10.45	0.42	0.95	39622
2026-03-26	OMER	10.31	0.43	0.08	40051
2026-03-27	OMER	9.89	0.43	0.23	40381
2026-03-30	OMER	9.82	0.43	0.09	40937
2026-03-31	OMER	10.57	0.41	0.60	42286
2026-04-01	OMER	12.07	0.38	0.13	45692
2026-04-06	OMER	10.88	0.39	0.03	48201
2026-04-07	OMER	10.99	0.37	0.35	50267
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

16 items 1 of 1

20 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-03-09	OMER	11.28	164.9	-	-1.25
2026-03-10	OMER	11.72	164.9	-	-1.25
2026-03-11	OMER	11.93	164.9	-	-1.25
2026-03-12	OMER	11.42	164.9	-	-1.25
2026-03-13	OMER	11.19	164.9	-	-1.25
2026-03-17	OMER	11.28	164.9	-	-1.25
2026-03-18	OMER	10.95	164.9	-	-1.25
2026-03-19	OMER	11.10	164.9	-	-1.25
2026-03-20	OMER	11.02	164.9	-	-1.25
2026-03-23	OMER	10.66	164.9	-	-1.25
2026-03-24	OMER	10.19	164.9	-	-1.25
2026-03-25	OMER	10.46	164.9	-	-1.25
2026-03-26	OMER	10.30	164.9	-	-1.25
2026-03-27	OMER	9.89	164.9	-	-1.25
2026-03-30	OMER	9.81	164.9	-	-1.25
2026-03-31	OMER	10.58	164.9	-	-1.25
2026-04-01	OMER	12.06	164.9	-	-1.25
2026-04-02	OMER	10.88	164.9	-	-1.25
2026-04-06	OMER	10.89	38.5	-	-1.54
2026-04-07	OMER	10.98	38.5	-	-1.54
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

20 items 1 of 1

19 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-03-09	OMER	-2.16	0.53	26.34
2026-03-10	OMER	-2.16	0.53	26.34
2026-03-11	OMER	-2.16	0.53	25.36
2026-03-12	OMER	-2.16	0.53	25.36
2026-03-13	OMER	-2.16	0.53	25.36
2026-03-18	OMER	-2.16	0.65	25.36
2026-03-19	OMER	-2.16	0.65	25.36
2026-03-20	OMER	-2.16	0.65	25.36
2026-03-23	OMER	-2.16	0.64	25.36
2026-03-24	OMER	-2.16	0.64	25.36
2026-03-25	OMER	-2.16	0.64	25.39
2026-03-26	OMER	-2.16	0.64	25.39
2026-03-27	OMER	-2.16	0.64	25.39
2026-03-30	OMER	-2.16	0.64	25.39
2026-03-31	OMER	-2.16	0.64	25.39
2026-04-01	OMER	-2.16	0.64	25.39
2026-04-02	OMER	-2.16	0.64	25.39
2026-04-06	OMER	-2.16	0.63	25.39
2026-04-07	OMER	-2.16	0.63	25.39
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

19 items 1 of 1

Last Quarter Act. EPS

3.14

Avg. EPS Est. Current Quarter

0.16

Avg. EPS Est. Next Quarter

-0.39

Insider Transactions

-2.16

Institutional Transactions

0.63

Beta

2.59

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

43.4

Max Drawdown 5-Year %

-94.4

Target Price

43.67

P/E

Forward P/E

13.43

PEG

P/S

P/B

P/Free Cash Flow

EPS

-0.5

Average EPS Est. Cur. Y

-1.54

EPS Next Y. (Est.)

1.31

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

0.87

Return on Equity vs Sector %

-24.7

Return on Equity vs Industry %

-8.2

EPS 1 7Days Diff

-2

EPS 1 30Days Diff

-2.03

EBIT Estimation

◆ OMER Healthcare

$10.98

📉

Swing / Pullback

Buy the dip on strong trends

N/A

WEAK

Trend

6/20

Pullback

17/25

Volume

4/15

Valuation

13/20

TP/AR

3/10

Options

8/10

RSI

49.5

Range 1M

31.3%

Sup Dist

3.2%

🚀

Momentum Growth

Ride accelerating trends

N/A

WEAK

Momentum

3/25

Growth

16/30

Estimates

2/20

Inst/Vol

4/15

Options

8/10

EPS Yr

-415%

EPS NY

417.5%

52W%

53.3%

💎

Long-Term Value

Quality companies, undervalued

N/A

WEAK

🟢 BUY +311.9% upside

Quality

2/30

Valuation

16/30

Growth

13/25

Stability

7/10

LT Trend

1/5

Upside

+311.9%

Quality

Omeros Corporation

Sector: Healthcare

Industry: Biotechnology

Employees: 175

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company's lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinical trial to treat COVID-19 and acute respiratory distress syndrome. It also develops OMS1029 that has completed phase I clinical trials for mannan-binding lectin-associated serine protease 2 (MASP-2) and lectin pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders, as well as cocaine use disorder. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; OncotoX-AML, to treat acute myeloid leukemia; and Targeted Complement Activating Therapy, for Multidrug-resistant organisms. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.

OMER

Latest News

—

Caricamento notizie per OMER…

stock quote shares OMER – Omeros Corporation Stock Price stock today

news today OMER – Omeros Corporation stock forecast ,stock prediction 2023 2024 2025

marketwatch OMER – Omeros Corporation yahoo finance google finance

stock history OMER – Omeros Corporation invest stock market

stock prices OMER premarket after hours

ticker OMER fair value insiders trading

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Upside

Beta

Ticker: OMER

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Latest News

Last Quarter Act. EPS

Average EPS Est. Cur. Y